Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 7/2013

01-07-2013 | Original Article

Seizures in systemic sclerosis

Authors: Fernando Glasner Araújo, Tiago Nardi Amaral, Simone Appenzeller, Jozélio Freire de Carvalho

Published in: Rheumatology International | Issue 7/2013

Login to get access

Abstract

The aim of this study was to evaluate the frequency of seizures in systemic sclerosis (SSc) and to determine the clinical and laboratory features associated with their occurrence. Thirty-four SSc patients (ACR criteria) were analyzed by a standard interview, physical examination, and review of medical charts. Risk factors for seizures, clinical manifestations, associated co-morbidities and current treatment were evaluated. We identified 3 (8.8 %) SSc patients with seizures. A higher median age [61 (35–64) vs. 48 (27–71) years, p = 0.0005] and higher activity score [4.75 (4.5–5.0) vs. 2.5 (0–5–5) years, p = 0.006] were observed in SSc patients with seizures. No other clinical or laboratory feature was associated with the occurrence of seizure in this cohort. This study demonstrated a higher prevalence of seizures in SSc when compared to general population. Seizures were associated with older age and higher activity score in this cohort.
Literature
1.
Medsger TA Jr, Masi AT (1971) Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 74:714–721PubMedCrossRef
2.
Gordon RM, Silverstein A (1970) Neurologic manifestations in progressive systemic sclerosis. Arch Neurol 22:126–134PubMedCrossRef
3.
Hietaharju A, Jääskeläinen S, Kalimo H, Hietarinta M (1993) Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve 16:1204–1212PubMedCrossRef
4.
Mohamed RHA, Nassef AA (2010) Brain magnetic resonance imaging findings in patients with systemic sclerosis. Int J Rheum Dis 13:61–67PubMedCrossRef
5.
Mohammed RHA, Sabry YY, Nasef AA (2011) Brain MRI screening showing evidences of early central nervous system involvement in patients with systemic sclerosis. Rheumatol Int 31:667–671PubMedCrossRef
6.
Jimenez-Moreno J, Selva-O’Callaghan A, Rovira-Cañellas A, Solans-Laque R, Len O, Olias M, Fonollosa-Pla V, Vilardell-Tarres M (1998) Trigeminal sensory neuropathy in systemic sclerosis. Br J Rheumatol 37:587–589PubMedCrossRef
7.
Bondavalli P, Parodi A, Rebora A (1997) Peripheral neuropathy in scleroderma successfully treated with amitriptyline. Int J Dermatol 36:234–235PubMedCrossRef
8.
Allanore Y, Zuber M, Kahan A (2002) Brachial plexopathy associated with systemic sclerosis. Clin Rheumatol 21:401–402PubMedCrossRef
9.
Hietaharju A, Jääskeläinen S, Hietarinta M, Frey H (1993) Central nervous system involvement and psychiatric manifestations in systemic sclerosis (scleroderma): clinical and neurophysiological evaluation. Acta Neurol Scand 87:382–387PubMed
10.
Navon P, Halevi A, Brand A, Branski D, Rubinow A (1993) Progressive systemic sclerosis sine scleroderma in a child presenting as nocturnal seizures and Raynaud’s phenomenon. Acta Paediatr 82:122–123PubMedCrossRef
11.
Ishii A, Oguni E, Yoshizawa T, Mizusawa H, Muraki R (1993) A case of progressive systemic sclerosis with Sjögren’s syndrome presenting with coma, convulsion and bilateral thalamic hypodensity on computed tomography. Rinsho Shinkeigaku 33:966–970PubMed
12.
Uriuhara A, Morita S, Yamada K, Masugi J, Yamada H, Hasegawa Y, Yokono K, Kasuga M (1997) A case of MPO-ANCA positive progressive systemic sclerosis with status epileptics. Ryumachi 37:483–486PubMed
13.
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980). Arthritis Rheum 23:581–590
14.
LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
15.
Furst DE, Clements PJ, Steen VD et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25:84–88PubMed
16.
Valentini G, Silman AJ, Veale D (2003) Assessment of disease activity. Clin Exp Rheumatol 21(3 Suppl 29):S39–S41PubMed
17.
Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(3 Suppl 29):S42–S46PubMed
18.
Benseñor IM, Lotufo PA, Menezes PR, Scazufca M (2010) Subclinical hyperthyroidism and dementia: the São Paulo Ageing & Health Study (SPAH). BMC Public Health 10:298PubMedCrossRef
19.
Blume WT, Lüders HO, Mizrahi E, Tassinari C, van Emde Boas W, Engel J Jr (2001) Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 42:1212–1218PubMedCrossRef
20.
Fisher RS, van Emde Boas W, Blume W et al (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46:470–472PubMedCrossRef
21.
Appenzeller S, Cendes F, Costallat LT (2004) Epileptic seizures in systemic lupus erythematosus. Neurology 63:1808–1812PubMedCrossRef
22.
Das CP, Prabhakar S, Lal V, Kharbanda PS (2002) Scleroderma, stroke, optic neuropathy: a rare association. Neurol India 50:504–507PubMed
23.
Clements PJ, Furst DE, Campion DS et al (1978) Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 21:62–71PubMedCrossRef
24.
Averbuch-Heller Steiner I, Abramsky O (1992) Neurologic manifestation of progressive systemic sclerosis. Arch Neurol 49:1292–1295PubMedCrossRef
25.
Lucivero V, Mezzapesa DM, Petruzzellis M, Carella A, Lamberti P, Federico F (2004) Ischaemic stroke in progressive systemic sclerosis. Neurol Sci 25:230–233PubMedCrossRef
26.
Sardanelli F, Lozzelli A, Cotticelli B et al (2005) White matter hyperintensities on brain magnetic resonance in systemic sclerosis. Ann Rheum Dis 64:777–779PubMedCrossRef
27.
28.
Fornes P, Chatellier J, Emmerich J et al (2002) Central nervous system involvement in scleroderma. Ann Med Interne 153:179–182
29.
Andonopoulos AP, Maraziotis T, Yarmenitis S et al (1998) Multiple spontaneous intracerebral haemorrhage in a patient with progressive systemic sclerosis. Rev Rheum (ENGL ED) 65:437–440
30.
Cutolo M, Nobili F, Sulli A et al (2000) Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology 39:1366–1373PubMedCrossRef
31.
32.
Forsgren L, Beghi E, Oun A, Sillanpää M (2005) The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurol 12(4):245–253PubMedCrossRef
33.
Grosso S, Fioravanti A, Biasi G, Conversano E, Marcolongo R, Morgese G, Balestri P (2003) Linear scleroderma associated with progressive brain atrophy. Brain Dev 25:57–61PubMedCrossRef
34.
Kister I, Inglese M, Laxer R, Herbert J (2008) Neurologic manifestations of localized scleroderma. Neurology 71:1538–1545PubMedCrossRef
35.
Stone J, Franks AJ, Guthrie JA, Johnson MH (2001) Scleroderma ‘en coup de sabre’: pathological evidence of intracerebral inflammation. J Neurol Neurosurg Psychiatry 70:382–385PubMedCrossRef
36.
Menni S, Marzano AV, Passoni E (1997) Neurologic abnormalities in two patients with facial hemiatrophy and sclerosis coexisting with morphea. Pediatr Dermatol 14:113–116PubMedCrossRef
37.
Blaszczyk M, Jablonska S (1999) Linear scleroderma en Coup de Sabre: relationship with progressive facial hemiatrophy (PFH). Adv Exp Med Biol 455:101–104PubMedCrossRef
38.
Dupont S, Catala M, Hasboun D, Semah F, Baulac M (1997) Progressive facial hemiatrophy and epilepsy: a common underlying dysgenetic mechanism. Neurology 48:1013–1018PubMedCrossRef
Metadata
Title
Seizures in systemic sclerosis
Authors
Fernando Glasner Araújo
Tiago Nardi Amaral
Simone Appenzeller
Jozélio Freire de Carvalho
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2630-y

Other articles of this Issue 7/2013

Rheumatology International 7/2013 Go to the issue

Original Article

Rheumatic manifestations of euthyroid, anti-thyroid antibody-positive patients

Original Article

Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis

Original Article

Is phonophoresis effective in the treatment of chronic low back pain? A single-blind randomized controlled trial

Letter to the Editors

Posterior ischemic optic neuropathy in a patient with granulomatosis with polyangiitis (Wegener’s)

Letter to the Editors

Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients

Short Communication

Relapsing polychondritis in childhood: three case reports, comparison with adulthood disease and literature review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits